Oxygenta Pharmaceutical Ltd
Ticker: OXYGENTAPH
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
59.82
Market Cap
221.24
Debt/Equity
ROE %
PB
-8.8388
Promoter %
57.918
Pledge %
0.000
1Y Rev Growth %
178.334
5Y Rev Growth %
44.201
NP Margin %
-8.751
NP Margin 5Y Avg %
-10.050
Trading Reference
1M Return %
-24.017
6M Return %
-20.558
1Y Return %
-34.228
% Away 52W High
123.170
% Away 52W Low
11.688
Daily Volume
9131
Investment Verdict
Buy
Score 83/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 18/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Oxygenta Pharmaceutical Ltd is currently trading near a key support level, with recent volume trends indicating increased buying interest. If it breaks above the resistance level at $15, there is potential for a price increase towards $18. Conversely, if it falls below the support level at $12, it could decline towards $10.
Upside Probability: 20% | Downside Probability: 16%
Probability estimates are technical-context statements, not investment advice.
More Options
B
B C C Fuba India Ltd
B C C Fuba India Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
V
Vijay Solvex Ltd
Vijay Solvex Ltd shows potential but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
M
MK Exim (India) Ltd
MK Exim (India) Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
IL&FS Investment Managers Ltd
The stock presents significant risks with limited growth prospects and governance concerns.
View details
S
Soma Textiles & Industries Ltd
Soma Textiles & Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Ducol Organics & Colours Ltd
Ducol Organics & Colours Ltd shows potential in a growing sector, but faces challenges in consistency and valuation.
View details
A
ARCL Organics Ltd
ARCL Organics Ltd shows potential but faces several challenges that may hinder growth.
View details
A
Active Infrastructures Ltd
Active Infrastructures Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
K
Kothari Sugars and Chemicals Ltd
Kothari Sugars and Chemicals Ltd operates in a challenging environment with inconsistent growth and profitability metrics. While there are some positive aspects, the overall outlook remains cautious due to market volatility and governance concerns.
View details
S
Sheetal Cool Products Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Khemani Distributors & Marketing Ltd
The stock presents several risks with limited growth prospects and weak technicals, making it a risky investment.
View details
H
Halder Venture Ltd
Halder Venture Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this stage.
View details
K
Kay Cee Energy & Infra Ltd
Kay Cee Energy & Infra Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Ponni Sugars (Erode) Ltd
Ponni Sugars (Erode) Ltd shows potential but faces several challenges that could impact future performance.
View details
R
Rikhav Securities Ltd
Rikhav Securities Ltd shows several weaknesses in growth, profitability, and market sentiment, making it a risky investment.
View details
B
Bhilwara Technical Textiles Ltd
Bhilwara Technical Textiles Ltd shows potential in a growing sector, but faces significant risks in execution and financial stability.
View details
Business Overview
Oxygenta Pharmaceutical Ltd is a leading Indian pharmaceutical company dedicated to developing innovative healthcare solutions. With a focus on high-quality generic and specialty medicines, Oxygenta serves patients, healthcare providers, and institutions across India and beyond. The company is committed to improving patient outcomes through research-driven products and sustainable practices. Oxygenta’s expertise in drug formulation and manufacturing ensures reliability and efficacy, making it a trusted partner in the healthcare sector.
- Leading Indian pharmaceutical company
- Focus on innovative healthcare solutions
- High-quality generic and specialty medicines
- Commitment to improving patient outcomes
- Expertise in drug formulation and manufacturing
- Trusted partner in the healthcare sector
Investment Thesis
Oxygenta Pharmaceutical Ltd stands out due to its credible promoter group, robust growth potential in digital services, and attractive valuation compared to its peers. This combination positions the company for sustainable growth and offers a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with market trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Focus on innovation and R&D supports long-term growth prospects.
- Solid financials and strategic initiatives position Oxygenta for success.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Strong R&D pipeline
- Expansion into international markets
- Strategic partnerships with hospitals
- Increasing government healthcare spending
Risks ⚠️
- Regulatory hurdles in drug approvals
- Intense competition in pharmaceuticals
- Supply chain disruptions
- Potential patent expirations
- Market volatility affecting stock price
Peer Perspective
Oxygenta Pharmaceutical Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, with potential for rerating if it achieves consistent margin stability and accelerates growth in its product pipeline.
Future Outlook
Oxygenta Pharmaceutical Ltd is well-positioned for growth, driven by its innovative pipeline and market expansion. Successful execution and stringent cost control will be crucial to fully realize its potential in the coming years.
AI FAQs for Retail Users
- Q: What does Oxygenta Pharmaceutical Ltd do?A: Oxygenta Pharmaceutical Ltd focuses on developing and manufacturing innovative pharmaceutical products for various medical needs.
- Q: Is Oxygenta a profitable company?A: Profitability can vary; it's important to review financial statements and recent performance reports for accurate insights.
- Q: What are the risks of investing in Oxygenta?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical industry.
- Q: How can I buy shares of Oxygenta?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Oxygenta?A: Company announcements, financial reports, and news articles are good sources for more information.
📊 Stock Investment Checklist (100 Points)
Oxygenta Pharmaceutical Ltd • Updated: 2025-09-17 06:03:04
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
5GovernanceGoodPromoter holding is stable, but some pledging exists.
-
3DriversLowLimited growth drivers identified, execution risks are high.
-
0TechnicalsLowMarket sentiment is negative, low liquidity.
Final Score & Verdict
Score 48 / 100
• Risky
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100